APO Research
Talk to an analyst

APO RESEARCH · REPORT

Humanized Bispecific Antibody

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Humanized Bispecific Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025197 pages

Choose your research edition.

Industry ResearchHumanized Bispecific Antibody Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Humanized Bispecific Antibody Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Humanized Bispecific Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Humanized Bispecific Antibody Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Humanized Bispecific Antibody Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Humanized Bispecific Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Humanized Bispecific Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Humanized Bispecific Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Humanized Bispecific Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Humanized Bispecific Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Humanized Bispecific Antibody include Tuowei Biotechnology, Genor Biopharma, Hansoh Pharmaceutical, Doma Biopharmaceutical, Dizal Pharma, Betta Pharmaceuticals, Biocytogen Co., Ltd., EpimAb Biotherapeutics and Allist, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Humanized Bispecific Antibody market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Humanized Bispecific Antibody and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Humanized Bispecific Antibody sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Humanized Bispecific Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.

Humanized Bispecific Antibody Segment by Company

Tuowei Biotechnology

Genor Biopharma

Hansoh Pharmaceutical

Doma Biopharmaceutical

Dizal Pharma

Betta Pharmaceuticals

Biocytogen Co., Ltd.

EpimAb Biotherapeutics

Allist

MacroGenics

Johnson & Johnson

AstraZeneca

Humanized Bispecific Antibody Segment by Type

IgG-like Double Antibody

Fragmented Dual Antibody (FAD)

Others

Humanized Bispecific Antibody Segment by Application

Oncology Treatment

Immune Disease Treatment

Infectious Disease Control

Others

Humanized Bispecific Antibody Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Humanized Bispecific Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Humanized Bispecific Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Humanized Bispecific Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Humanized Bispecific Antibody market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Humanized Bispecific Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Humanized Bispecific Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Humanized Bispecific Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Humanized Bispecific Antibody Industry Trends Table 2. Humanized Bispecific Antibody Industry Drivers Table 3. Humanized Bispecific Antibody Industry Opportunities and Challenges Table 4. Humanized Bispecific Antibody Industry Restraints Table 5. Global Humanized Bispecific Antibody Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Humanized Bispecific Antibody Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Humanized Bispecific Antibody Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Humanized Bispecific Antibody Sales Market Share by Manufacturers Table 9. Global Humanized Bispecific Antibody Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Humanized Bispecific Antibody Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Humanized Bispecific Antibody Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Humanized Bispecific Antibody Manufacturers, Product Type & Application Table 13. Global Humanized Bispecific Antibody Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Humanized Bispecific Antibody by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of IgG-like Double Antibody Table 17. Major Manufacturers of Fragmented Dual Antibody (FAD) Table 18. Major Manufacturers of Others Table 19. Global Humanized Bispecific Antibody Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Humanized Bispecific Antibody Sales by Type (2021-2026) & (K Units) Table 21. Global Humanized Bispecific Antibody Sales by Type (2027-2032) & (K Units) Table 22. Global Humanized Bispecific Antibody Sales Market Share by Type (2021-2026) Table 23. Global Humanized Bispecific Antibody Sales Market Share by Type (2027-2032) Table 24. Global Humanized Bispecific Antibody Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Humanized Bispecific Antibody Revenue by Type (2021-2026) & (K Units) Table 26. Global Humanized Bispecific Antibody Revenue by Type (2027-2032) & (K Units) Table 27. Global Humanized Bispecific Antibody Revenue Market Share by Type (2021-2026) Table 28. Global Humanized Bispecific Antibody Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Oncology Treatment Table 30. Major Manufacturers of Immune Disease Treatment Table 31. Major Manufacturers of Infectious Disease Control Table 32. Major Manufacturers of Others Table 33. Global Humanized Bispecific Antibody Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Humanized Bispecific Antibody Sales by Application (2021-2026) & (K Units) Table 35. Global Humanized Bispecific Antibody Sales by Application (2027-2032) & (K Units) Table 36. Global Humanized Bispecific Antibody Sales Market Share by Application (2021-2026) Table 37. Global Humanized Bispecific Antibody Sales Market Share by Application (2027-2032) Table 38. Global Humanized Bispecific Antibody Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Humanized Bispecific Antibody Revenue by Application (2021-2026) & (K Units) Table 40. Global Humanized Bispecific Antibody Revenue by Application (2027-2032) & (K Units) Table 41. Global Humanized Bispecific Antibody Revenue Market Share by Application (2021-2026) Table 42. Global Humanized Bispecific Antibody Revenue Market Share by Application (2027-2032) Table 43. Global Humanized Bispecific Antibody Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Humanized Bispecific Antibody Sales by Region (2021-2026) & (K Units) Table 45. Global Humanized Bispecific Antibody Sales Market Share by Region (2021-2026) Table 46. Global Humanized Bispecific Antibody Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Humanized Bispecific Antibody Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Humanized Bispecific Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Humanized Bispecific Antibody Sales by Country (2021-2026) & (K Units) Table 50. North America Humanized Bispecific Antibody Sales by Country (2027-2032) & (K Units) Table 51. Europe Humanized Bispecific Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Humanized Bispecific Antibody Sales by Country (2021-2026) & (K Units) Table 53. Europe Humanized Bispecific Antibody Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Humanized Bispecific Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Humanized Bispecific Antibody Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Humanized Bispecific Antibody Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Humanized Bispecific Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Humanized Bispecific Antibody Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Humanized Bispecific Antibody Sales by Country (2027-2032) & (K Units) Table 60. Global Humanized Bispecific Antibody Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Humanized Bispecific Antibody Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Humanized Bispecific Antibody Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Humanized Bispecific Antibody Revenue Market Share by Region (2021-2026) Table 64. Global Humanized Bispecific Antibody Revenue Market Share by Region (2027-2032) Table 65. Tuowei Biotechnology Company Information Table 66. Tuowei Biotechnology Business Overview Table 67. Tuowei Biotechnology Humanized Bispecific Antibody Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Tuowei Biotechnology Humanized Bispecific Antibody Product Portfolio Table 69. Tuowei Biotechnology Recent Development Table 70. Genor Biopharma Company Information Table 71. Genor Biopharma Business Overview Table 72. Genor Biopharma Humanized Bispecific Antibody Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Genor Biopharma Humanized Bispecific Antibody Product Portfolio Table 74. Genor Biopharma Recent Development Table 75. Hansoh Pharmaceutical Company Information Table 76. Hansoh Pharmaceutical Business Overview Table 77. Hansoh Pharmaceutical Humanized Bispecific Antibody Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Hansoh Pharmaceutical Humanized Bispecific Antibody Product Portfolio Table 79. Hansoh Pharmaceutical Recent Development Table 80. Doma Biopharmaceutical Company Information Table 81. Doma Biopharmaceutical Business Overview Table 82. Doma Biopharmaceutical Humanized Bispecific Antibody Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Doma Biopharmaceutical Humanized Bispecific Antibody Product Portfolio Table 84. Doma Biopharmaceutical Recent Development Table 85. Dizal Pharma Company Information Table 86. Dizal Pharma Business Overview Table 87. Dizal Pharma Humanized Bispecific Antibody Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Dizal Pharma Humanized Bispecific Antibody Product Portfolio Table 89. Dizal Pharma Recent Development Table 90. Betta Pharmaceuticals Company Information Table 91. Betta Pharmaceuticals Business Overview Table 92. Betta Pharmaceuticals Humanized Bispecific Antibody Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Betta Pharmaceuticals Humanized Bispecific Antibody Product Portfolio Table 94. Betta Pharmaceuticals Recent Development Table 95. Biocytogen Co., Ltd. Company Information Table 96. Biocytogen Co., Ltd. Business Overview Table 97. Biocytogen Co., Ltd. Humanized Bispecific Antibody Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Biocytogen Co., Ltd. Humanized Bispecific Antibody Product Portfolio Table 99. Biocytogen Co., Ltd. Recent Development Table 100. EpimAb Biotherapeutics Company Information Table 101. EpimAb Biotherapeutics Business Overview Table 102. EpimAb Biotherapeutics Humanized Bispecific Antibody Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. EpimAb Biotherapeutics Humanized Bispecific Antibody Product Portfolio Table 104. EpimAb Biotherapeutics Recent Development Table 105. Allist Company Information Table 106. Allist Business Overview Table 107. Allist Humanized Bispecific Antibody Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Allist Humanized Bispecific Antibody Product Portfolio Table 109. Allist Recent Development Table 110. MacroGenics Company Information Table 111. MacroGenics Business Overview Table 112. MacroGenics Humanized Bispecific Antibody Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. MacroGenics Humanized Bispecific Antibody Product Portfolio Table 114. MacroGenics Recent Development Table 115. Johnson & Johnson Company Information Table 116. Johnson & Johnson Business Overview Table 117. Johnson & Johnson Humanized Bispecific Antibody Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Johnson & Johnson Humanized Bispecific Antibody Product Portfolio Table 119. Johnson & Johnson Recent Development Table 120. AstraZeneca Company Information Table 121. AstraZeneca Business Overview Table 122. AstraZeneca Humanized Bispecific Antibody Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. AstraZeneca Humanized Bispecific Antibody Product Portfolio Table 124. AstraZeneca Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. Humanized Bispecific Antibody Distributors List Table 128. Humanized Bispecific Antibody Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Humanized Bispecific Antibody Product Image Figure 2. Global Humanized Bispecific Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Humanized Bispecific Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global Humanized Bispecific Antibody Sales (2021-2032) & (K Units) Figure 5. Global Humanized Bispecific Antibody Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Humanized Bispecific Antibody Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. IgG-like Double Antibody Image Figure 9. Fragmented Dual Antibody (FAD) Image Figure 10. Others Image Figure 11. Global Humanized Bispecific Antibody Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Humanized Bispecific Antibody Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Humanized Bispecific Antibody Sales Market Share by Type (2021-2032) Figure 14. Global Humanized Bispecific Antibody Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Humanized Bispecific Antibody Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Humanized Bispecific Antibody Revenue Market Share by Type (2021-2032) Figure 17. Oncology Treatment Image Figure 18. Immune Disease Treatment Image Figure 19. Infectious Disease Control Image Figure 20. Others Image Figure 21. Global Humanized Bispecific Antibody Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Humanized Bispecific Antibody Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Humanized Bispecific Antibody Sales Market Share by Application (2021-2032) Figure 24. Global Humanized Bispecific Antibody Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Humanized Bispecific Antibody Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Humanized Bispecific Antibody Revenue Market Share by Application (2021-2032) Figure 27. North America Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Humanized Bispecific Antibody Sales Market Share by Country (2021-2032) Figure 29. U.S. Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Humanized Bispecific Antibody Sales Market Share by Country (2021-2032) Figure 34. Germany Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Humanized Bispecific Antibody Sales Market Share by Country (2021-2032) Figure 41. China Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Humanized Bispecific Antibody Sales Market Share by Country (2021-2032) Figure 49. Brazil Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Humanized Bispecific Antibody Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Humanized Bispecific Antibody Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Humanized Bispecific Antibody Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Humanized Bispecific Antibody Revenue (2021-2032) & (US$ Million) Figure 60. North America Humanized Bispecific Antibody Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Humanized Bispecific Antibody Revenue (2021-2032) & (US$ Million) Figure 62. Europe Humanized Bispecific Antibody Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Humanized Bispecific Antibody Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Humanized Bispecific Antibody Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Humanized Bispecific Antibody Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Humanized Bispecific Antibody Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Humanized Bispecific Antibody Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Humanized Bispecific Antibody Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • IgG-like Double Antibody
  • Fragmented Dual Antibody (FAD)
  • Others
Applications
  • Oncology Treatment
  • Immune Disease Treatment
  • Infectious Disease Control
  • Others
Companies covered
  • Tuowei Biotechnology
  • Genor Biopharma
  • Hansoh Pharmaceutical
  • Doma Biopharmaceutical
  • Dizal Pharma
  • Betta Pharmaceuticals
  • Biocytogen Co., Ltd.
  • EpimAb Biotherapeutics
  • Allist
  • MacroGenics
  • Johnson & Johnson
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Humanized Bispecific Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Humanized Bispecific Antibody Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Humanized Bispecific Antibody Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Humanized Bispecific Antibody Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Humanized Bispecific Antibody Market Dynamics
  1. 2.1 Humanized Bispecific Antibody Industry Trends
  2. 2.2 Humanized Bispecific Antibody Industry Drivers
  3. 2.3 Humanized Bispecific Antibody Industry Opportunities and Challenges
  4. 2.4 Humanized Bispecific Antibody Industry Restraints
3 Humanized Bispecific Antibody Market by Manufacturers
  1. 3.1 Global Humanized Bispecific Antibody Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Humanized Bispecific Antibody Sales by Manufacturers (2021-2026)
  3. 3.3 Global Humanized Bispecific Antibody Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Humanized Bispecific Antibody Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Humanized Bispecific Antibody Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Humanized Bispecific Antibody Manufacturers, Product Type & Application
  7. 3.7 Global Humanized Bispecific Antibody Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Humanized Bispecific Antibody Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Humanized Bispecific Antibody Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Humanized Bispecific Antibody Tier 1, Tier 2, and Tier 3
4 Humanized Bispecific Antibody Market by Type
  1. 4.1 Humanized Bispecific Antibody Type Introduction
  2. 4.1.1 IgG-like Double Antibody
  3. 4.1.2 Fragmented Dual Antibody (FAD)
  4. 4.1.3 Others
  5. 4.2 Global Humanized Bispecific Antibody Sales by Type
  6. 4.2.1 Global Humanized Bispecific Antibody Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Humanized Bispecific Antibody Sales by Type (2021-2032)
  8. 4.2.3 Global Humanized Bispecific Antibody Sales Market Share by Type (2021-2032)
  9. 4.3 Global Humanized Bispecific Antibody Revenue by Type
  10. 4.3.1 Global Humanized Bispecific Antibody Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Humanized Bispecific Antibody Revenue by Type (2021-2032)
  12. 4.3.3 Global Humanized Bispecific Antibody Revenue Market Share by Type (2021-2032)
5 Humanized Bispecific Antibody Market by Application
  1. 5.1 Humanized Bispecific Antibody Application Introduction
  2. 5.1.1 Oncology Treatment
  3. 5.1.2 Immune Disease Treatment
  4. 5.1.3 Infectious Disease Control
  5. 5.1.4 Others
  6. 5.2 Global Humanized Bispecific Antibody Sales by Application
  7. 5.2.1 Global Humanized Bispecific Antibody Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Humanized Bispecific Antibody Sales by Application (2021-2032)
  9. 5.2.3 Global Humanized Bispecific Antibody Sales Market Share by Application (2021-2032)
  10. 5.3 Global Humanized Bispecific Antibody Revenue by Application
  11. 5.3.1 Global Humanized Bispecific Antibody Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Humanized Bispecific Antibody Revenue by Application (2021-2032)
  13. 5.3.3 Global Humanized Bispecific Antibody Revenue Market Share by Application (2021-2032)
6 Global Humanized Bispecific Antibody Sales by Region
  1. 6.1 Global Humanized Bispecific Antibody Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Humanized Bispecific Antibody Sales by Region (2021-2032)
  3. 6.2.1 Global Humanized Bispecific Antibody Sales by Region (2021-2026)
  4. 6.2.2 Global Humanized Bispecific Antibody Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Humanized Bispecific Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Humanized Bispecific Antibody Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Humanized Bispecific Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Humanized Bispecific Antibody Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Humanized Bispecific Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Humanized Bispecific Antibody Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Humanized Bispecific Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Humanized Bispecific Antibody Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Humanized Bispecific Antibody Revenue by Region
  1. 7.1 Global Humanized Bispecific Antibody Revenue by Region
  2. 7.1.1 Global Humanized Bispecific Antibody Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Humanized Bispecific Antibody Revenue by Region (2021-2026)
  4. 7.1.3 Global Humanized Bispecific Antibody Revenue by Region (2027-2032)
  5. 7.1.4 Global Humanized Bispecific Antibody Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Humanized Bispecific Antibody Revenue (2021-2032)
  8. 7.2.2 North America Humanized Bispecific Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Humanized Bispecific Antibody Revenue (2021-2032)
  11. 7.3.2 Europe Humanized Bispecific Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Humanized Bispecific Antibody Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Humanized Bispecific Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Humanized Bispecific Antibody Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Humanized Bispecific Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Tuowei Biotechnology
  2. 8.1.1 Tuowei Biotechnology Company Information
  3. 8.1.2 Tuowei Biotechnology Business Overview
  4. 8.1.3 Tuowei Biotechnology Humanized Bispecific Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Tuowei Biotechnology Humanized Bispecific Antibody Product Portfolio
  6. 8.1.5 Tuowei Biotechnology Recent Developments
  7. 8.2 Genor Biopharma
  8. 8.2.1 Genor Biopharma Company Information
  9. 8.2.2 Genor Biopharma Business Overview
  10. 8.2.3 Genor Biopharma Humanized Bispecific Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Genor Biopharma Humanized Bispecific Antibody Product Portfolio
  12. 8.2.5 Genor Biopharma Recent Developments
  13. 8.3 Hansoh Pharmaceutical
  14. 8.3.1 Hansoh Pharmaceutical Company Information
  15. 8.3.2 Hansoh Pharmaceutical Business Overview
  16. 8.3.3 Hansoh Pharmaceutical Humanized Bispecific Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Hansoh Pharmaceutical Humanized Bispecific Antibody Product Portfolio
  18. 8.3.5 Hansoh Pharmaceutical Recent Developments
  19. 8.4 Doma Biopharmaceutical
  20. 8.4.1 Doma Biopharmaceutical Company Information
  21. 8.4.2 Doma Biopharmaceutical Business Overview
  22. 8.4.3 Doma Biopharmaceutical Humanized Bispecific Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Doma Biopharmaceutical Humanized Bispecific Antibody Product Portfolio
  24. 8.4.5 Doma Biopharmaceutical Recent Developments
  25. 8.5 Dizal Pharma
  26. 8.5.1 Dizal Pharma Company Information
  27. 8.5.2 Dizal Pharma Business Overview
  28. 8.5.3 Dizal Pharma Humanized Bispecific Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Dizal Pharma Humanized Bispecific Antibody Product Portfolio
  30. 8.5.5 Dizal Pharma Recent Developments
  31. 8.6 Betta Pharmaceuticals
  32. 8.6.1 Betta Pharmaceuticals Company Information
  33. 8.6.2 Betta Pharmaceuticals Business Overview
  34. 8.6.3 Betta Pharmaceuticals Humanized Bispecific Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Betta Pharmaceuticals Humanized Bispecific Antibody Product Portfolio
  36. 8.6.5 Betta Pharmaceuticals Recent Developments
  37. 8.7 Biocytogen Co., Ltd.
  38. 8.7.1 Biocytogen Co., Ltd. Company Information
  39. 8.7.2 Biocytogen Co., Ltd. Business Overview
  40. 8.7.3 Biocytogen Co., Ltd. Humanized Bispecific Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Biocytogen Co., Ltd. Humanized Bispecific Antibody Product Portfolio
  42. 8.7.5 Biocytogen Co., Ltd. Recent Developments
  43. 8.8 EpimAb Biotherapeutics
  44. 8.8.1 EpimAb Biotherapeutics Company Information
  45. 8.8.2 EpimAb Biotherapeutics Business Overview
  46. 8.8.3 EpimAb Biotherapeutics Humanized Bispecific Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 EpimAb Biotherapeutics Humanized Bispecific Antibody Product Portfolio
  48. 8.8.5 EpimAb Biotherapeutics Recent Developments
  49. 8.9 Allist
  50. 8.9.1 Allist Company Information
  51. 8.9.2 Allist Business Overview
  52. 8.9.3 Allist Humanized Bispecific Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Allist Humanized Bispecific Antibody Product Portfolio
  54. 8.9.5 Allist Recent Developments
  55. 8.10 MacroGenics
  56. 8.10.1 MacroGenics Company Information
  57. 8.10.2 MacroGenics Business Overview
  58. 8.10.3 MacroGenics Humanized Bispecific Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 MacroGenics Humanized Bispecific Antibody Product Portfolio
  60. 8.10.5 MacroGenics Recent Developments
  61. 8.11 Johnson & Johnson
  62. 8.11.1 Johnson & Johnson Company Information
  63. 8.11.2 Johnson & Johnson Business Overview
  64. 8.11.3 Johnson & Johnson Humanized Bispecific Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Johnson & Johnson Humanized Bispecific Antibody Product Portfolio
  66. 8.11.5 Johnson & Johnson Recent Developments
  67. 8.12 AstraZeneca
  68. 8.12.1 AstraZeneca Company Information
  69. 8.12.2 AstraZeneca Business Overview
  70. 8.12.3 AstraZeneca Humanized Bispecific Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AstraZeneca Humanized Bispecific Antibody Product Portfolio
  72. 8.12.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Humanized Bispecific Antibody Value Chain Analysis
  2. 9.1.1 Humanized Bispecific Antibody Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Humanized Bispecific Antibody Production Mode & Process
  6. 9.2 Humanized Bispecific Antibody Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Humanized Bispecific Antibody Distributors
  9. 9.2.3 Humanized Bispecific Antibody Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst